Trevi Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Trevi Therapeutics, Inc. (TRVI) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 13.63 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Trevi Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.89M shares, a 1.51% increase year-over-year.
- Trevi Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 13.69M shares, a 21.90% decline year-over-year.
- Trevi Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 17.53M shares, a 16.34% increase year-over-year.
- Trevi Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 15.06M shares, a 32.65% decline year-over-year.
- Trevi Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 11.15M shares, a 25.72% decline from fiscal 2024.
- Trevi Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 15.02M shares, a 0.00% change from fiscal 2023.
- Trevi Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 15.02M shares, a 6.09% increase from fiscal 2022.
- Trevi Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 14.15M shares, a 39.85% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 13.63M shares 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | 13.89M shares 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | 11.15M shares 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | 11.30M shares 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | 12.09M shares 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | 13.69M shares 10-Q · filed 2026-05-05 | ||||
| 2024-12-31 | 15.02M shares 10-K · filed 2026-03-17 | 17.55M shares 10-K · filed 2025-03-18 | |||
| 2024-09-30 | 17.64M shares 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | 17.67M shares 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | 17.53M shares 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 15.02M shares 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | 15.02M shares 10-Q · filed 2024-11-06 | ||||
| 2023-06-30 | 15.09M shares 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 15.06M shares 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | 14.15M shares 10-K · filed 2024-03-20 | ||||
| 2022-09-30 | 13.85M shares 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | 18.15M shares 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 22.37M shares 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 23.53M shares 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | 3.05M shares 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | 3.20M shares 10-Q · filed 2022-08-11 | ||||
| 2021-03-31 | 3.25M shares 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | 2.17M shares 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | 2.33M shares 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | 2.26M shares 10-Q · filed 2020-08-13 | ||||
| 2020-03-31 | 2.21M shares 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | 1.68M shares 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | 1.69M shares 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | 1.69M shares 10-Q · filed 2020-08-13 | ||||
| 2019-03-31 | 84.00M shares 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | 77.17M shares 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | 77.18M shares 10-Q · filed 2019-11-14 | ||||
| 2018-06-30 | 69.87M shares 10-Q · filed 2019-08-12 | ||||
| 2018-03-31 | 77.17M shares 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |